Christopher Yea - Net Worth and Insider Trading

Christopher Yea Net Worth

The estimated net worth of Christopher Yea is at least $797,493 dollars as of 2024-12-26. Christopher Yea is the CHIEF DEVELOPMENT OFFICER of KalVista Pharmaceuticals Inc and owns about 91,142 shares of KalVista Pharmaceuticals Inc (KALV) stock worth over $797,493. Details can be seen in Christopher Yea's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Christopher Yea has not made any transactions after 2024-11-26 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Christopher Yea

To

Christopher Yea Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Christopher Yea owns 1 companies in total, including KalVista Pharmaceuticals Inc (KALV) .

Click here to see the complete history of Christopher Yea’s form 4 insider trades.

Insider Ownership Summary of Christopher Yea

Ticker Comapny Transaction Date Type of Owner
KALV KalVista Pharmaceuticals Inc 2024-11-26 Chief Development Officer

Christopher Yea Latest Holdings Summary

Christopher Yea currently owns a total of 1 stock. Christopher Yea owns 91,142 shares of KalVista Pharmaceuticals Inc (KALV) as of November 26, 2024, with a value of $797,493.

Latest Holdings of Christopher Yea

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
KALV KalVista Pharmaceuticals Inc 2024-11-26 91,142 8.75 797,493

Holding Weightings of Christopher Yea


Christopher Yea Form 4 Trading Tracker

According to the SEC Form 4 filings, Christopher Yea has made a total of 21 transactions in KalVista Pharmaceuticals Inc (KALV) over the past 5 years, including 0 buys and 21 sells. The most-recent trade in KalVista Pharmaceuticals Inc is the sale of 1,963 shares on November 26, 2024, which brought Christopher Yea around $19,375.

Insider Trading History of Christopher Yea

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Christopher Yea Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Christopher Yea Ownership Network

Ownership Network List of Christopher Yea

No Data

Ownership Network Relation of Christopher Yea

Insider Network Chart

Christopher Yea Owned Company Details

What does KalVista Pharmaceuticals Inc do?

Who are the key executives at KalVista Pharmaceuticals Inc?

Christopher Yea is the Chief Development Officer of KalVista Pharmaceuticals Inc. Other key executives at KalVista Pharmaceuticals Inc include CFO and Secretary Benjamin L Palleiko , Chief Medical Officer Paul K. Audhya , and Chief Scientific Officer Edward P. Feener .

KalVista Pharmaceuticals Inc (KALV) Insider Trades Summary

Over the past 18 months, Christopher Yea made 9 insider transaction in KalVista Pharmaceuticals Inc (KALV) with a net sale of 95,977. Other recent insider transactions involving KalVista Pharmaceuticals Inc (KALV) include a net sale of 162,750 shares made by Benjamin L Palleiko , a net purchase of 1,251,017 shares made by Venrock Healthcare Capital Partners Iii, L.p. , and a net sale of 63,847 shares made by Paul K. Audhya .

In summary, during the past 3 months, insiders sold 41,446 shares of KalVista Pharmaceuticals Inc (KALV) in total and bought 0 shares, with a net sale of 41,446 shares. During the past 18 months, 607,982 shares of KalVista Pharmaceuticals Inc (KALV) were sold and 1,251,017 shares were bought by its insiders, resulting in a net purchase of 643,035 shares.

KalVista Pharmaceuticals Inc (KALV)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

KalVista Pharmaceuticals Inc Insider Transactions

No Available Data

Christopher Yea Mailing Address

Above is the net worth, insider trading, and ownership report for Christopher Yea. You might contact Christopher Yea via mailing address: One Kendall Square, Building 200, Suite 2203, Cambridge Ma 02139.

Discussions on Christopher Yea

No discussions yet.